Phase 3 Clinical Study of AK112 for NSCLC Patients

Inclusion Criteria:

1. Ability to understand and voluntarily sign a written informed consent form (ICF),which must be signed before the specified study procedures required for the studyare performed.

2. Males or females aged ≥ 18 to ≤ 75 years at the time of signing informed consent.

3. Eastern Cooperative Oncology Group (ECOG) Performance Status (PS) 0 or 1.

4. Life expectancy ≥3 months；

5. Locally advanced (stage IIIB/IIIC) or metastatic (stage IV) non-squamous NSCLCconfirmed by histology or cytology, inoperable and unable to receive radiotherapyand chemotherapy;

6. The tumor histology, cytology or hematology confirmed the presence of EGFRactivating mutations before enrollment

7. Have previously received EGFR-TKI treatment and the treatment has failed

8. Subjects have at least one measurable non-brain tumor lesion per RECIST v1.1

9. Major organ function prior to treatment meets the following criteria

10. Patients of childbearing potential must agree to use effective contraceptivemeasures

Exclusion Criteria:

1. Histological or cytological pathology confirmed the presence of small cell carcinomacomponents, or the main component is squamous cell carcinoma

2. There are reports confirming the existence of other driver gene mutations with knowndrug treatments

3. Subjects who received any prior treatments targeting the mechanism of tumor immunity

4. The subject has received systemic anti-tumor therapy other than EGFR-TKI

5. Currently enrolled in any other clinical study

6. Received EGFR-TKI treatment, palliative local treatment, non-specificimmunomodulatory treatment within 2 weeks prior to the first dose; and Chineseherbal medicine or traditional Chinese medicinal products with anti-tumorindications within 1 weeks prior to the first dose.

7. Tumor surrounds important blood vessels or has obvious necrosis, cavitation, orinvades surrounding important organs and blood vessels.

8. Symptomatic central nervous system metastases

9. Active malignancies within the past 3 years, with the exception of tumors in thisstudy and cured local tumors

10. Active autoimmune disease requiring systemic treatment within 2 years prior to thestart of study treatment

11. There is a history of major diseases 1 year prior to the first dose.

12. .Medical history of gastrointestinal perforation or gastrointestinal fistula within 6 months prior to the first dose

13. Received chest radiation therapy prior to the first dose

14. Presence of clinically symptomatic pleural effusion, pericardial effusion, orascites requiring frequent drainage.

15. Active or previously documented inflammatory bowel disease (e.g., Crohn's disease orulcerative colitis).